This document is a new patent application published by the USPTO, specifically application US20260083679A1, titled 'Adagrasib Solid Pharmaceutical Compositions for Treating Cancer'. It details pharmaceutical compositions in solid form comprising adagrasib, intended for oral dosage to treat cancer, along with manufacturing methods and treatment protocols. The application was filed on December 3, 2025, by inventors Cletus Nunes, Mehrdad Kheiripour, and Monika Gavireddi.

As this is a patent application, it does not impose immediate compliance obligations or deadlines on regulated entities. However, it signifies potential future intellectual property rights related to adagrasib-based cancer treatments. Companies involved in the development, manufacturing, or marketing of adagrasib or similar oncology drugs should monitor this patent application for potential licensing opportunities or to assess freedom to operate in this therapeutic area.